Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

Simple item page
dc.contributor.authorQuach, H.
dc.contributor.authorJoshua, D.
dc.contributor.authorHo, J.
dc.contributor.authorSzer, J.
dc.contributor.authorSpencer, A.
dc.contributor.authorHarrison, S.
dc.contributor.authorMollee, P.
dc.contributor.authorRoberts, A.
dc.contributor.authorHorvath, N.
dc.contributor.authorTalaulikar, D.
dc.contributor.authorTo, B.
dc.contributor.authorZannettino, A.
dc.contributor.authorBrown, R.
dc.contributor.authorCatley, L.
dc.contributor.authorAugustson, B.
dc.contributor.authorJaksic, W.
dc.contributor.authorGibson, J.
dc.contributor.authorPrince, H. M.
dc.date.accessioned2015-04-20T06:21:42Z
dc.date.available2015-04-20T06:21:42Z
dc.date.issued2015-03-03
dc.date.updated2024-02-11T07:15:18Z
dc.description.abstractOptions for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.
dc.description.sponsorshipCopyright Information: 2015 Royal Australasian College of Physicians
dc.identifier.issn1444-0903en_AU
dc.identifier.urihttp://hdl.handle.net/1885/13281
dc.publisherWiley
dc.rights© 2015 Royal Australasian College of Physicians
dc.sourceInternal Medicine Journal
dc.subjectelderly
dc.subjectmultiple myeloma
dc.subjecttherapy
dc.subjecttransplant ineligible
dc.titleTreatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group
dc.typeJournal article
dcterms.dateAccepted2014-12-20
local.bibliographicCitation.issue3en_AU
local.bibliographicCitation.lastpage343en_AU
local.bibliographicCitation.startpage335en_AU
local.contributor.affiliationTalaulikar, D., The Australian National Universityen_AU
local.contributor.authoruidu4283279en_AU
local.identifier.absfor119999 - Medical and Health Sciences not elsewhere classified
local.identifier.ariespublicationa383154xPUB1184
local.identifier.citationvolume45en_AU
local.identifier.doi10.1111/imj.12688en_AU
local.identifier.essn1445-5994en_AU
local.identifier.scopusID2-s2.0-84923823289
local.identifier.thomsonID000350646100015
local.publisher.urlhttp://au.wiley.com/WileyCDA/en_AU
local.type.statusPublished Versionen_AU

Downloads

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
884 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS